Viridian Therapeutics, Inc.
VRDN
$30.43
-$1.02-3.24%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.79M | 305.00K | 302.00K | 302.00K | 302.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.79M | 305.00K | 302.00K | 302.00K | 302.00K |
| Cost of Revenue | 250.60M | 233.49M | 203.06M | 203.99M | 170.59M |
| Gross Profit | -179.81M | -233.19M | -202.76M | -203.69M | -170.28M |
| SG&A Expenses | 77.23M | 67.31M | 63.16M | 61.08M | 78.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 398.91M | 371.89M | 337.31M | 299.34M | 283.34M |
| Operating Income | -328.12M | -371.59M | -337.01M | -299.04M | -283.04M |
| Income Before Tax | -301.97M | -344.06M | -308.32M | -269.95M | -257.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -301.97 | -344.06 | -308.32 | -269.95 | -257.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -301.97M | -344.06M | -308.32M | -269.95M | -257.08M |
| EBIT | -328.12M | -371.59M | -337.01M | -299.04M | -283.04M |
| EBITDA | -327.66M | -371.10M | -336.49M | -298.50M | -282.48M |
| EPS Basic | -2.45 | -2.99 | -2.76 | -2.48 | -2.33 |
| Normalized Basic EPS | -2.33 | -2.79 | -2.65 | -2.48 | -2.70 |
| EPS Diluted | -2.45 | -2.99 | -2.76 | -2.48 | -2.33 |
| Normalized Diluted EPS | -2.33 | -2.79 | -2.65 | -2.48 | -2.70 |
| Average Basic Shares Outstanding | 324.77M | 309.41M | 291.67M | 271.43M | 241.06M |
| Average Diluted Shares Outstanding | 324.77M | 309.41M | 291.67M | 271.43M | 241.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |